Clinicopathologic and biological parameters predicting the prognosis in endometrial cancer

Yonsei Medical Journal

Volumn 43, Issue 6, 2002, Pages 769-778

  Kim, Jae Wook ^a   Kim, Sung Hoon ^a   Kim, Young Tae ^a   Kim, Dong Kyu ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Biological parameters; Clinicopathologic parameters; Endometrial cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; CANCER INCIDENCE; CANCER STAGING; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE MARKER; ENDOMETRIUM CARCINOMA; EUROPE; FEMALE GENITAL TRACT CANCER; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; KOREA; LIFE EXPECTANCY; POSTMENOPAUSE; PREDICTION; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TUMOR VOLUME; UNITED STATES; UTERINE CERVIX CANCER;

EID: 0036954063     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2002.43.6.769     Document Type: Review

References (53)

1. Cancer Committee of Korean Obstetrics and Gynecology Association. Annual report of gynecologic cancer registry program in Korean for 1998. Korean J Obstet Gynecol 2001;44:425-59.
2. Berek JS, Adashi EY, Hillard PA. Novak's Gynecology. 12th ed. Baltimore: Williams & Willkins; 1996. p.1057-110.
3. DiSaia PJ, Creasman WT. Management of endometrial adenocarcinoma stage I with surgical staging followed by tailored adjuvant radiation therapy. Clin Obstet Gynecol 1986;13:751-65.
4. Wharton JT, Mikuta JJ, Mettlin C, Murphy GP, Synder CJ, Piver MS, et al. Risk factors and current management in carcinoma of the endometrium. Surg Gynecol Obstet 1986;162:515-20.
5. Vergote I, Kjorstad J, Abeler V, Kolstad P. A randomized trial of adjuvant progestogen in early endometrial cancer. Cancer 1989;64:1011-6.
6. Morrow CP, Bundy BN, Homesley H, Creasman WT, Hornback NB, Kurman R, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II. Gynecol Oncol 1990;36:166-71.
7. Stringer CA, Gershenson DM, Burke TW, Edwards CL, Gordon AN, Wharton JT. Adjuvant chemotherapy with cisplatin, doxorubicin and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis. Gynecol Oncol 1990;38:305-8.
8. Crissman JD, Azoury RS, Banner ARE, Schellas HF, Endometrial carcinoma in women 40years of age or younger. Obstet Gynecol 1981;57:699-704.
9. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynecol 1980;56:419-46.
10. Lurian JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Miller DS. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 1991;78:63-9.
11. Kottmeier HL. Annual reports on the results of treatment in carcinoma of the uterus, vagina and ovary. Gynecol Oncol 1976;4:13-9.
12. Abeler VM, Kjorstad KE, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer 1992;2:9-72.
13. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. Cancer 1987;60:2035-41.
14. Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 1984;63:825-32.
15. Jones HW. Treatment of adenocarcinoma of the endometrium. Obstet Gynecol Surv 1975;30:147-69.
16. Creasman WT, DiSaia PJ, Blessing J, Wilkinson RH Jr, Johnston W, Weed JC Jr. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol 1981;141:921-9.
17. Lurain JR, Rumsey NK, Schink JC, Wallemark CB, Chmiel JS. Prognostic significance of positive peritoneal cytology in clinical stage I adenocarcinoma of endometrium. Obstet Gynecol 1989;74:175-9.
18. Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology in an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 1992;46:145-9.
19. Morrow DH, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
20. DiSaia PJ, Creasman WT, Boronow RC, Blessing JA. Risk factors and recurrent patterns in stage I endometrial cancer. Am J Obstet Gynecol 1985;151:1009-15.
21. Hanson MB, Van Nagell Jr, Powell DE, Donaldson ES, Gallion H, Merhige M, et al. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer 1985;55:1753-7.
22. Schink JC, Lurain JR, Wallemark CB, Chmiel JS. Tumor size in endometrial cancer: a prognostic factor for lymph node metastasis. Obstet Gynecol 1987;70:216-9.
23. Martin JD, Hahnel R, McCartney AJ, Woodings TL. The effect of estrogen receptor status on survival in patients with endometrial cancer. Am J Obstet Gynecol 1983;147:322-4.
24. Creasman WT, Soper JT, McCarty KS Jr, McCarty KS Sr, Hinshaw W, Clarke-Pearson DL. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 1985;151:922-32.
25. Liao BS, Twiggs LB, Leung BS, Yu WC, Potish RA, Prem KA. Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial carcinoma. Obstet Gynecol 1986;67:463-7.
26. Geisinger KR, Homesley HD, Morgan TM, Kute TE, Marshall RB. Endometrial adenocarcinoma: a multi-parameter clinicopathologic analysis including the DNA profile and sex hormone receptors. Cancer 1986;58:1518-25.
27. Palmer DC, Muir IM, Alexander AI, Cauchi M, Bennett RC, Quinn MA. The prognostic importance of steroid receptors in endometrial carcinoma. Obstet Gynecol 1988;72:388-93.
28. Morrow CP, Schlaerth JB. Surgical management of endometrial carcinoma. Clin Obstet Gynecol 1982;25:81-92.
29. Iverson OE. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 1986;155:770-6.
30. Stendahl U, Strang P, Wagenius G, Bergstrom R, Tribukait B. Prognostic significance of proliferation in endometrial adenocarcinomas: a multivariate analysis of clinical and flow cytometric variables. Int J Gynaecol Pathol 1991;10:271-84.
31. Panici PB, Scambia G, Baiocchi G, Perrone L, Greggi S, Battaglia F, et al. Multiple serum markers in patients with endometrial cancer. Gynecol Obstet Invest 1989;27:208-12.
32. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 1986;155:1097-102.
33. Fujimoto I. Shimizu Y, Hirai Y,Chen JT, Teshima H, Hasumi K, et al. Studies on ras oncogene activation in endometrial carcinoma. Gynecol Oncol 1993;48:196-202.
34. Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garrett CT. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 1992;52:2777-81.
35. Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982;28:865-71.
36. Czerwenka K, Lu Y, Heuss F. Amplification and expression of the c-erbB-2 oncogene in normal, hyperplastic, and, malignant endometrium. Int J Gynecol Pathol 1995;14:98-106.
37. Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF. Amplification and overexpression of HER-2/neu (c-erbB-2) in endometrial cancers: correlation with overall survival. Cancer Res 1995;55:5693-8.
38. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
39. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. P53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98:81-7.
40. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995;85(5 pt 1):729-34.
41. Saegusa M, Okayasu I. Bcl-2 is closely correlated with favorable prognostic factors and inversely with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings. J Cancer Res Clin 1997,123:429-34.
42. Taskin M, Lallas TA, Barber HR, Shevchuk MM. Bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 1997;10:728-34.
43. Chhieng DC, Ross JS, Ambros RA. Bcl-2 expression and the development of endometrial carcinoma. Mod Pathol 1996;9:402-6.
44. Miturski R, Semczuk A, Tomaszewski J, Jakowicki J. Bcl-2 protein expression in endometrial carcinoma: the lack of correlation with p53. Cancer Lett 1998;133:63-9.
45. Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Romanini C. Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients. Gynecol Oncol 1996;61:16-21.
46. Sasano H, Nagura H, Watanabe K, Ito K, Tsuiki A, Sato S, et al. Tenascin expression in normal and abnormal human endometrium. Mod Pathol 1993;6:323-6.
47. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
48. Yang WI, Chumng KY, Shin DH, Kim YB. Cyclin D1 protein expression in lung cancer. Yonsei, Med J 1996;37:142-50.
49. Ito K, Sasano H, Matsunaga G, Sato S, Yajima A, Nasim S, et al. Correlation between p2l expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 1997;183:318-24.
50. Backe J, Gassel AM, Hauber K, Kerbs S, Bartek J, Caffier H, et al. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol 1997;16:361-8.
51. Vogel HP, Mendelsohn G. Laminin immunostaining in hyperplastic, dysplastic and neoplastic lesions of the endometrium and uterine cervix. Obstet Gynecol 1987;69:794-9.
52. Maudelonde T, Martinez P, Brouillet JP, Laffargue F, Pages A, Rochefort H. Cathepsin-D in human endometrium: induction by progesterone and potential value as a tumor marker. J Clin Endocr Metab 1990;70:115-21.
53. Inoue M, Ogawa H, Miyata M, Shiozaki H, Tanizawa O. Expression of E-cadherin in normal benign and malignant tissues of female genital organs. Am J Clin Pathol 1992;98:76-80.